Recent studies indicated that STC2 was overexpressed in hepatocellular carcinoma, neuroblastoma, glioblastoma, renal cell carcinoma, esophageal squamous cell cancer, prostate, gastric, lung, head and neck, and ovarian cancers (14)(15), and high expression of STC2 in all above-mentioned tumors was correlated with the increased tumor growth, migration, invasion, increased incidence of nodal and distant metastasis, decreased survival and overall poor prognosis (6)(16). This evidence concerns the gene STC2 and ovarian carcinoma.